Shares of SpringWorks Therapeutics, Inc. (SWTX) have rallied 45.8% in the past year against the industry’s decline of 6.7%.Earlier this month, the company completed the new drug application (NDA) submission for its investigational MEK inhibitor, mirdametinib, which is being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients.In March 2024, the company initiated the rolling submission of the NDA to the FDA for mirdametinib in N ...